SA519402103B1 - 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط - Google Patents

1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط

Info

Publication number
SA519402103B1
SA519402103B1 SA519402103A SA519402103A SA519402103B1 SA 519402103 B1 SA519402103 B1 SA 519402103B1 SA 519402103 A SA519402103 A SA 519402103A SA 519402103 A SA519402103 A SA 519402103A SA 519402103 B1 SA519402103 B1 SA 519402103B1
Authority
SA
Saudi Arabia
Prior art keywords
cdk4
naphthyridine
inhibitor
compounds
disclosed
Prior art date
Application number
SA519402103A
Other languages
English (en)
Inventor
زد. دينغ تشارلز
زو زهاوبينج
تشن شوهوي
هو ليهونغ
Original Assignee
ستون للادوية
شركة ستون للادوية (سوتشو) المحدودة
شركة ستون للادوية (شنغهاي) المحدودة
ميدشاين ديسكوفري انك.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ستون للادوية, شركة ستون للادوية (سوتشو) المحدودة, شركة ستون للادوية (شنغهاي) المحدودة, ميدشاين ديسكوفري انك. filed Critical ستون للادوية
Publication of SA519402103B1 publication Critical patent/SA519402103B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

يتعلق الاختراع الحالي بالكشف عن سلسلة من المركبات التي تعمل كمثبطات inhibitors ل CDK4/6. على وجه التحديد، يتم الكشف عن مركبات على النحو الممثل من خلال الصيغة (I)، وأملاح مقبولة صيدلانية pharmaceutically acceptable salts أو أيزومرات isomers منها، وتركيبات صيدلانية تحتوي عليها، واستخدامها في تحضير العقاقير preparation of drugs من أجل علاج السرطانات treating cancers. .
SA519402103A 2016-12-16 2019-06-15 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط SA519402103B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611170508 2016-12-16
CN201710787583 2017-09-04

Publications (1)

Publication Number Publication Date
SA519402103B1 true SA519402103B1 (ar) 2022-04-05

Family

ID=62558021

Family Applications (1)

Application Number Title Priority Date Filing Date
SA519402103A SA519402103B1 (ar) 2016-12-16 2019-06-15 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط

Country Status (14)

Country Link
US (1) US10676474B2 (ar)
EP (1) EP3556758A1 (ar)
JP (1) JP7044801B2 (ar)
KR (1) KR102513448B1 (ar)
CN (1) CN110382495B (ar)
AU (1) AU2017374721B2 (ar)
BR (1) BR112019012176A2 (ar)
CA (1) CA3046864A1 (ar)
IL (1) IL267299B (ar)
MX (1) MX2019006843A (ar)
RU (1) RU2747311C2 (ar)
SA (1) SA519402103B1 (ar)
TW (1) TWI749126B (ar)
WO (1) WO2018108167A1 (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110382495B (zh) * 2016-12-16 2022-04-05 基石药业（苏州）有限公司 Cdk4/6抑制剂
CN112292379B (zh) * 2018-06-13 2022-03-04 基石药业（苏州）有限公司 吡啶并吡啶酮衍生物的盐型及晶型
CN114340634A (zh) * 2019-07-02 2022-04-12 诺维逊生物股份有限公司 作为激酶抑制剂的杂环化合物
WO2021110122A1 (zh) * 2019-12-05 2021-06-10 基石药业（苏州）有限公司 Cdk4/6抑制剂的组合疗法
CN115551856A (zh) * 2020-02-28 2022-12-30 重庆复尚源创医药技术有限公司 作为cdk2/4/6抑制剂的化合物
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CN116063307A (zh) * 2021-10-29 2023-05-05 中国药科大学 Shp2与cdk4/6双靶点抑制化合物合成及其制备方法与应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009030A1 (en) * 1997-08-20 1999-02-25 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
IL162721A0 (en) 2002-01-22 2005-11-20 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyridoÄ2,3-dÜpyrimidin-7-ones
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
BRPI0509580A (pt) 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
BRPI0511065A (pt) 2004-06-04 2007-12-26 Pfizer Prod Inc método para tratar crescimento de célula anormal
WO2008032157A2 (en) 2006-09-08 2008-03-20 Pfizer Products Inc. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2009126584A1 (en) 2008-04-07 2009-10-15 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
JO2885B1 (ar) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني مثبطات بروتين كيناز
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
ES2689177T3 (es) 2010-04-13 2018-11-08 Novartis Ag Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer
ES2525866T3 (es) 2010-08-05 2014-12-30 Temple University - Of The Commonwealth System Of Higher Education 8-alquil-7-oxo-7,8-dihidropirido [2,3-d]pirimidina-6-carbonitrilos sustituidos en 2 y usos de los mismos
MY161199A (en) 2011-03-23 2017-04-14 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
WO2014052365A1 (en) * 2012-09-26 2014-04-03 Mannkind Corporation Multiple kinase pathway inhibitors
EP3431475B1 (en) 2013-02-21 2021-04-07 Pfizer Inc Solid forms of a selective cdk4/6 inhibitor
WO2014183520A1 (zh) * 2013-05-17 2014-11-20 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2016015598A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
WO2017101763A1 (en) * 2015-12-13 2017-06-22 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as anti-cancer agents
CN110382495B (zh) * 2016-12-16 2022-04-05 基石药业（苏州）有限公司 Cdk4/6抑制剂

Also Published As

Publication number Publication date
IL267299A (ar) 2019-07-31
CN110382495A (zh) 2019-10-25
WO2018108167A1 (zh) 2018-06-21
US10676474B2 (en) 2020-06-09
JP2020510083A (ja) 2020-04-02
RU2019121926A (ru) 2021-01-18
EP3556758A4 (en) 2019-10-23
AU2017374721B2 (en) 2021-02-25
JP7044801B2 (ja) 2022-03-30
AU2017374721A1 (en) 2019-08-01
CA3046864A1 (en) 2018-06-21
TW201823246A (zh) 2018-07-01
MX2019006843A (es) 2019-11-11
RU2747311C2 (ru) 2021-05-04
RU2019121926A3 (ar) 2021-01-18
TWI749126B (zh) 2021-12-11
EP3556758A1 (en) 2019-10-23
KR102513448B1 (ko) 2023-03-23
BR112019012176A2 (pt) 2019-11-05
KR20190092549A (ko) 2019-08-07
IL267299B (en) 2022-09-01
CN110382495B (zh) 2022-04-05
US20190315745A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2015017192A (es) Inhibidores de fosfatidilinositol 3-cinasa.
JO3474B1 (ar) مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
MX2016016538A (es) Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa.
WO2015191754A3 (en) Phosphatidylinositol 3-kinase inhibitors
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
MX2016016528A (es) Inhibidores de fosfatidilinositol 3-quinasa.
PH12016502539A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
MX2020001719A (es) Inhibidores macrocíclicos de mcl-1 y metodos de uso.
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
PH12018502376B1 (en) Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
NZ738247A (en) 4-(3-pyrazolylamino)-benzimidazole compounds and their use as jak1 inhibitors